Tenatoprazole

Tenatoprazole

Clinical data
Routes of administration	Oral
ATC code	none
Pharmacokinetic data
Metabolism	Hepatic (CYP2C19-mediated)
Elimination half-life	4.8 to 7.7 hours
Identifiers
IUPAC name 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine
CAS Number	113712-98-4  Y
PubChem CID	636411
ChemSpider	552196  Y
UNII	RE0689TX2K
CompTox Dashboard (EPA)	DTXSID1046687
ECHA InfoCard	100.120.697
Chemical and physical data
Formula	C16H18N4O3S
Molar mass	346.41 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES Cc1c(OC)c(C)cnc1CS(=O)c2[nH]c3ccc(OC)nc3n2
InChI InChI=1S/C16H18N4O3S/c1-9-7-17-12(10(2)14(9)23-4)8-24(21)16-18-11-5-6-13(22-3)19-15(11)20-16/h5-7H,8H2,1-4H3,(H,18,19,20) Y Key:ZBFDAUIVDSSISP-UHFFFAOYSA-N Y
(verify)

Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003. ^[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007 ^[2] ). ^{[3] : 22}

Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007 ^{[4] : 27} and again in 2012. ^{[3] : 17}

Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs. ^[5]

See also

• Imidazopyridine

References

1. "Gastrointestinal Disease Update". Digestive Disease Week. DataMonitor. March 2003.
2. "Investors unwilling to forgive Wockhardt, promoter for failings". Economic Times. 3 March 2011. Archived from the original on November 16, 2014.
3. "State of New Product Development" (PDF). Mitsubishi Tanabe Pharma. 8 May 2012. Archived from the original (PDF) on 9 November 2012. Retrieved 16 November 2014.
4. "FY2007 Interim Financial Results". Mitsubishi Tanabe Pharma.^{[ permanent dead link ]}
5. Li H, Meng L, Liu F, Wei JF, Wang YQ (January 2013). "H+/K+-ATPase inhibitors: a patent review". Expert Opinion on Therapeutic Patents. 23 (1): 99–111. doi:10.1517/13543776.2013.741121. PMID   23205582. S2CID   44647770.